CERo Therapeutics Holdings, Inc. · OTC:CERO

CERo Therapeutics Holdings, Inc. financial statements

CERo Therapeutics Holdings, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2023FY2022
Research and development5.29M
Operating income-7.68M-2.91M
Interest expense-138.3K
Income before tax-19.9M-2.44M-68.6K
Income tax94.8K599.2K
Net income-19.9M-7.29M-667.7K
Earnings per share, basic-0.24-1,248.64-0.05
Earnings per share, diluted-1,248.64

Balance sheet

LineFY2025FY2023FY2022
Cash and equivalents1.70M96.9K475.9K
Current assets2.73M1.97M42.4M
Property, plant and equipment246.1K966.7K
Total assets3.64M5.13M42.4M
Accounts payable7.58M1.67M
Current liabilities9.09M3.51M30.7M
Total liabilities9.09M5.08M39.9M
Shareholders' equity-5.45M-42.1M-11.0M
Shares outstanding83.3M5.84K14.7M

Cash flow

LineFY2025FY2023FY2022
Cash from operations-16.1M-1.52M-1.09M
Cash from investing-7.94M180.8M
Cash from financing-32.6M-138.7M
Dividends paid-127.1K
Share buybacks-33.5M-139.4M
Change in cash-42.0M41.0M